9vhpv vaccine
Anal Intraepithelial Neoplasia
Merck Sharp & Dohme LLCvaccinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Anal Intraepithelial Neoplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
9-valent human papillomavirus recombinant vaccine Xiamen University | Phase 3 | BB |
ACETIC ACID, TRICHLORO- University Hospital, Essen | N/A | D |
Same molecule, other indications
9vhpv vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →